The FDA’s Pressure-Packed Alzheimer’s Drug Decision

The U.S. Food and Drug Administration faces a costly and consequential decision over whether to approve a controversial new Alzheimer’s drug.


Caleb Alexander, Professor of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health

View the transcript for today's episode:

Take our short listener survey, and you could win a $50 gift card!

Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff:

Support this type of journalism today, with a gift:

Follow us on Twitter:


See for privacy and opt-out information.